全文获取类型
收费全文 | 24021篇 |
免费 | 2089篇 |
国内免费 | 825篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 345篇 |
妇产科学 | 306篇 |
基础医学 | 2150篇 |
口腔科学 | 300篇 |
临床医学 | 1765篇 |
内科学 | 5480篇 |
皮肤病学 | 424篇 |
神经病学 | 1429篇 |
特种医学 | 204篇 |
外国民族医学 | 6篇 |
外科学 | 1710篇 |
综合类 | 2154篇 |
现状与发展 | 14篇 |
预防医学 | 412篇 |
眼科学 | 332篇 |
药学 | 5758篇 |
7篇 | |
中国医学 | 471篇 |
肿瘤学 | 3579篇 |
出版年
2024年 | 64篇 |
2023年 | 571篇 |
2022年 | 857篇 |
2021年 | 1254篇 |
2020年 | 1034篇 |
2019年 | 951篇 |
2018年 | 959篇 |
2017年 | 932篇 |
2016年 | 811篇 |
2015年 | 989篇 |
2014年 | 1495篇 |
2013年 | 2398篇 |
2012年 | 1309篇 |
2011年 | 1551篇 |
2010年 | 1136篇 |
2009年 | 1171篇 |
2008年 | 1252篇 |
2007年 | 1112篇 |
2006年 | 1049篇 |
2005年 | 941篇 |
2004年 | 773篇 |
2003年 | 646篇 |
2002年 | 501篇 |
2001年 | 409篇 |
2000年 | 318篇 |
1999年 | 291篇 |
1998年 | 243篇 |
1997年 | 238篇 |
1996年 | 210篇 |
1995年 | 186篇 |
1994年 | 143篇 |
1993年 | 129篇 |
1992年 | 99篇 |
1991年 | 113篇 |
1990年 | 119篇 |
1989年 | 86篇 |
1988年 | 76篇 |
1987年 | 44篇 |
1986年 | 54篇 |
1985年 | 80篇 |
1984年 | 69篇 |
1983年 | 46篇 |
1982年 | 48篇 |
1981年 | 46篇 |
1980年 | 33篇 |
1979年 | 22篇 |
1978年 | 24篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
A M Abdel Gader A A Al-Mishari S A Awadalla N M Buyuomi T Khashoggi M Al-Hakeem 《International journal of gynaecology and obstetrics》2006,95(3):248-253
OBJECTIVE: To clarify the role played by tissue factor pathway inhibitor (TFPI) in pregnancy hypertension. METHODS: Using enzyme-linked immunosorbent assays, hemostatic measurements were obtained for women with pre-eclampsia (n=51), nonproteinuric hypertension of pregnancy (n=62), postpartum pre-eclampsia 24 h after childbirth (n=31), and no hypertension (healthy pregnant controls, n=100). RESULTS: There was a significant increase in circulating free TFPI levels in women with pre-eclampsia (9.7+/-6.2 ng/mL) or nonproteinuric hypertension of pregnancy (8.3+/-5.3 ng/mL) compared with healthy controls (5.3+/-2.1 ng/mL). In women with pre-eclampsia the levels remained elevated after placental delivery (10.6+/-4.0 ng/mL). Free protein S levels were significantly higher in women with pre-eclampsia (40.0%+/-10.7%), nonproteinuric hypertension of pregnancy (37.1%+/-12.5%), or postpartum pre-eclampsia (39.3%+/-9.1%) than in healthy pregnant controls (32.2%+/-8.5%). CONCLUSION: Increased levels of the physiologically active free forms of TFPI and free protein S, 2 coagulation inhibitors, may protect women with pregnancy-induced hypertension from the risks of hemostatic activation. 相似文献
72.
Summary. Patients with mild or moderate haemophilia A usually have a mild bleeding disorder requiring only occasional treatment with factor VIII (FVIII) concentrates. The frequency of inhibitor development in such patients has been the subject of several recent surveys, which significantly modified our appreciation of this complication. Studies of the anti-FVIII antibodies provided an explanation for the different bleeding phenotypes observed in mild/moderate haemophilia A patients with inhibitors. Antibodies distinguishing between the patient's mutant FVIII and the normal wild-type FVIII were characterized, in addition to antibodies inhibiting completely or only partially FVIII activity. T lymphocytes recognizing FVIII and likely involved in the development of the immune response to FVIII were successfully identified. The FVIII peptides recognized by those FVIII-specific cells bind to many major histocompatibility complex (MHC) class II molecules, which may provide an explanation for the lack of strong association between MHC haplotypes and inhibitor development. Although these studies have advanced our understanding of the conditions leading to inhibitor development, further work is required to determine whether the mode of FVIII administration significantly influences inhibitor development. Further studies of the genetic factors are also required to fully understand the mechanisms leading to inhibitor development in patients with mild/moderate haemophilia A. 相似文献
73.
高脂血症对血浆t-PA和PAI-1活性的影响 总被引:2,自引:0,他引:2
目的 探讨高脂血症患者的纤溶系统的变化。方法 选取正常人及高脂血症者,测定其血脂、血浆t—PA和PAI-1活性。结果 高脂血症组比正常人血浆t—PA活性下降,而PAI-1的活性有升高;在TG及LDL-C升高者,其血浆t—PA活性比正常人血浆t—PA活性降低,而血浆PAI-1活性比正常人升高;单纯TC升高者血浆PAI-1活性接近正常人组,而血浆t—PA活性比正常人组明显降低。结论 高脂血症对纤溶系统有一定的影响,其中甘油三酯和LDL-C对纤溶系统的影响更明显,而胆固醇对纤溶系统也有一定的影响。 相似文献
74.
Alex W Wilson Stephen J Medhurst Claire I Dixon Nick C Bontoft Lisa A Winyard Kim T Brackenborough Jorge De Alba Christopher J Clarke Martin J Gunthorpe Gareth A Hicks Chas Bountra Daniel S McQueen Iain P Chessell 《European Journal of Pain》2006,10(6):537-549
Clinically, inflammatory pain is far more persistent than that typically modelled pre-clinically, with the majority of animal models focussing on short-term effects of the inflammatory pain response. The large attrition rate of compounds in the clinic which show pre-clinical efficacy suggests the need for novel models of, or approaches to, chronic inflammatory pain if novel mechanisms are to make it to the market. A model in which a more chronic inflammatory hypersensitivity phenotype is profiled may allow for a more clinically predictive tool. The aims of these studies were to characterise and validate a chronic model of inflammatory pain. We have shown that injection of a large volume of adjuvant to the intra-articular space of the rat knee results in a prolonged inflammatory pain response, compared to the response in an acute adjuvant model. Additionally, this model also results in a hypersensitive state in the presence and absence of inflammation. A range of clinically effective analgesics demonstrate activity in this chronic model, including morphine (3mg/kg, t.i.d.), dexamethasone (1mg/kg, b.i.d.), ibuprofen (30mg/kg, t.i.d.), etoricoxib (5mg/kg, b.i.d.) and rofecoxib (0.3-10mg/kg, b.i.d.). A further aim was to exemplify the utility of this chronic model over the more acute intra-plantar adjuvant model using two novel therapeutic approaches; NR2B selective NMDA receptor antagonism and iNOS inhibition. Our data shows that different effects were observed with these therapies when comparing the acute model with the model of chronic inflammatory joint pain. These data suggest that the chronic model may be more relevant to identifying mechanisms for the treatment of chronic inflammatory pain states in the clinic. 相似文献
75.
2005~2007年我国非甾体抗炎药市场应用分析 总被引:1,自引:0,他引:1
目的:以骨骼肌肉系统使用非甾体抗炎药物为例,分析该类药物在2005~2007年的销售数量、销售金额及生产厂家风云榜。方法:采用药物分类累加的方法统计2005~2007年非甾体抗炎药的销售数量和金额排序,并对前10位药品销售数量和金额对比,及前10位厂家对比。结果:双氯芬酸稳居销售榜首,美洛昔康、布洛芬等药物位居其后。结论:新一代的非甾体抗炎药已经占据主要市场,各类药物各有特色,但是仍需注意其消化系统及心血管系统的不良反应。 相似文献
76.
77.
All cells that constitute mature tissues in an eukaryotic organism undergo a multistep process of cell differentiation. At
the terminal stage of this process, cells either cease to proliferate forever or rest for a very long period of time. During
terminal differentiation, most of the genes that are required for cell ‘housekeeping’ functions, such as proto-oncogenes and
other cell-cycle and cell proliferation genes, become stably repressed. At the same time, nuclear chromatin undergoes dramatic
morphological and structural changes at the higher-order levels of chromatin organization. These changes involve both constitutively
inactive chromosomal regions (constitutive heterochromatin) and the formerly active genes that become silenced and structurally
modified to form facultative heterochromatin. Here we approach terminal cell differentiation as a unique system that allows
us to combine biochemical, ultrastructural and molecular genetic techniques to study the relationship between the hierarchy
of chromatin higher-order structures in the nucleus and its function(s) in dynamic packing of genetic material in a form that
remains amenable to regulation of gene activity and other DNA-dependent cellular processes. 相似文献
78.
派立明与贝特舒联合应用对降眼压的临床观察 总被引:1,自引:0,他引:1
目的评价1.00%派立明(AZOPT)与0.25%贝特舒点眼液每日两次点眼对原发性开角型青光眼、高眼压症及抗青光眼术后高眼压的降眼压效果及安全性。方法31例患者51只眼纳入为期2个月的前瞻性研究。在停用其他抗青光眼药物足够长的时间后测量基础值,用药后每2周复查一次共4次,同时观察眼局部及全身副作用。结果用药前眼压为23.85±1.80 mmHg,4次随访眼压下降均值6.55 mmHg(6.06~7.04),眼压下降率27.50%(26.62~28.59%)。少数病例出现烧灼感、视物模糊、口苦等症状,均为轻度能耐受,对视力、眼底无影响。结论派立明与贝特舒联合用药具有稳定的降眼压效果,具良好耐受性。 相似文献
79.
《Journal of labelled compounds & radiopharmaceuticals》2003,46(13):1241-1247
Tritium was introduced into the new orally active, selective phosphodiesterase type V (PDE V) inhibitor vardenafil (Levitra®), by reduction of a suitable amide precursor with freshly prepared lithium aluminum tritide. A specific activity of 52.7 Ci/mmol (1.95 TBq/mmol) was achieved. In order to overcome the usual technical difficulties during the preparation of complex tritides a new and easy labeling technique which has considerable potential for various tritia‐tion procedures, was developed. Copyright © 2003 John Wiley & Sons, Ltd. 相似文献
80.
TAKUJI INAGAKI md TADAHIRO SHIKIMI phd HIROSHI ISHINO md HIDEKI OKUNISHI md SHUJI TAKAORI md 《Psychiatry and clinical neurosciences》1995,49(5-6):287-290
Abstract Relationships between urinary levels of α1-microglobulin (α1M) and ulinastatin (UT) in patients with dementia were investigated. There were no significant differences in α1M and UT levels and α1M: UT ratios among three groups: age-matched control subjects, patients with either Alzheimer-type senile dementia (ATD) or vascular dementia (VD). Although a positive correlation was established between α1M and UT levels in these groups, the regression of the demented patients differed significantly from that of controls ( P <0.05). A tendency towards a negative correlation between α1M: UT ratios and the levels of severity or duration of the disease was displayed in the ATD group, whereas a tendency toward a positive correlation between α1M: UT ratios and the levels of severity was observed in the VD group. These results suggest that changes in the relationships between urinary levels of α1M and UT may provide a useful biochemical index for diagnoses of ATD and VD. 相似文献